From Culture to Cryo: Smarter Cell Washing and Pre-Formulation for Allogeneic Therapies

In allogeneic cell therapy manufacturing, cell washing and pre-formulation mark the final point of control before cells are filled, frozen, and shipped – whether processing iPSCs, MSCs, NK cells, CAR-T cells, or other donor-derived immune cell types. These steps must efficiently remove residual media, preserve viability, and prepare the product for storage or clinical use—without compromising quality or consistency. Yet many workflows still rely on open systems, manual handling, or separation methods not optimized for sensitive cell types. The result is often variable recovery, inconsistent buffer exchange, and a higher risk of contamination. Cell washing and pre-formulation aren’t just end-of-line steps—they’re essential to ensuring the integrity of the final product.

Rethinking Cell Harvesting: A Strategic Lever in Allogeneic Therapy Production

In allogeneic therapies, harvested cells are the final product—or a critical intermediate—making gentle cell separation and recovery essential to overall process performance. Losses at this stage can compromise potency, reduce yield, and introduce variability that can carry through to downstream operations. Protecting cell health while achieving high recovery is essential, especially as production scales and regulatory expectations intensify. In this context, cell harvesting is not just a technical step but a strategic opportunity to improve product quality, process reliability, and overall manufacturing success.

Overcoming Scale-Up Challenges in iPSC Production